Based on transcription profiles of patients, tumor immune evasion capacity is assessed by TIDE, which represents the degree of tumor immune dysfunction and exclusion, indicating the response for anti-PD-1/PD-L1 and anti CTLA-4 therapies (Fu et al., 2020). This evidence concerns the gene CTLA4 and neoplasm.